FDA sends warning letter to 3 major formula makers over quality control concerns

  • 📰 abc7newsbayarea
  • ⏱ Reading Time:
  • 47 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 22%
  • Publisher: 51%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

The FDA has just sent new warning letters to three formula companies, red-flagging quality control concerns.

Normally fully stocked shelves of baby forumala are empty in a Target store in Queens, New York, June 23, 2022.The FDA has sent warning letters to three formula companies, red-flagging concerns about serious quality control issues at some manufacturing facilities.

Two of the infants subsequently died, though Abbott maintains no conclusive evidence has proven its formula caused the babies' illnesses. But Abbott's ultimate shutdown ricocheted from coast to coast, leaving a serious void in the market and forcing families to face empty shelves and scramble for alternatives for months.

The letters describe multiple occasions where the FDA says finished formula tested positive for Cronobacter and instances where the companies had failed to sufficiently investigate the contamination's source and prevent it from happening again. Reckitt also found Cronobacter in their finished formula product at multiple facilities in the fall of 2022.

FDA investigators say they also found Cronobacter from swabbing their facility's environment this March -- noting in their letter that this "was not the first time" they had found it at that facility.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 529. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Outlook Therapeutics’ stock tumbles 71% premarket after FDA rejects treatment for wet AMDOutlook Therapeutics Inc.’s stock tumbled 71% in premarket trade Wednesday, after the company said the U.S. Food and Drug Administration has issued a Control...
Source: MarketWatch - 🏆 3. / 97 Read more »